

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2008

DEL CATH SYSTEMS, INC.

(Exact Name of Registrant as Specified in Charter)

DELAWARE

(State of Incorporation)

001-16133

(Commission  
File Number)

06-1245881

(IRS Employer  
Identification No.)

600 FIFTH AVENUE, 23<sup>rd</sup> FLOOR  
NEW YORK, NEW YORK

(Address of Principal Executive Offices)

10020

(Zip Code)

Registrant's telephone number, including area code: (212) 489-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective December 5, 2008 (the "Effective Date"), the Board of Directors of Delcath Systems, Inc. (the "Company") elected Roger G. Stoll as a Director. Mr. Stoll's election was recommended by the Nominating & Governance Committee and approved by the unanimous action of the full Board of Directors. See Exhibit 99.1 attached hereto for biographical information about Mr. Stoll.

Mr. Stoll will receive the director fees and benefits described in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 24, 2008. In addition, he was awarded on the Effective Date under the Company's 2004 Stock Incentive Plan (the "Plan") options to purchase 75,000 shares of the Company's common stock at an exercise price per share equal to the Fair Market Value thereof on the Effective Date determined in accordance with the Plan. There are no other material transactions between Mr. Stoll and the Company.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

Exhibit  
Number Description

99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 10, 2008

DELCATH SYSTEMS, INC.

By: /s/ Paul M. Feinstein

\_\_\_\_\_  
Name: Paul M. Feinstein

Title: Chief Financial Officer

**Delcath Adds Senior Medical Professional to Its Board of Directors**

**NEW YORK, December 9, 2008** - Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Roger G. Stoll, Ph.D. to Delcath's Board of Directors. Dr. Stoll is Executive Chairman, of Cortex Pharmaceuticals, Inc. (Amex: COR), a biotechnology company specializing in the treatment of central nervous system disorders.

Prior to joining Cortex, Dr. Stoll worked as a consultant to several east coast venture capital firms and startup venture companies. From 1998 to 2001, Dr. Stoll was Executive Vice-President of Fresenius Medical Care - North America, a leading manufacturer and distributor of dialysis products, including hemodialysis machines and filters, and operator of more than 1,500 outpatient dialysis clinics in the United States.

From 1991 to 1998, he was President and Chief Executive Officer of Ohmeda, a global pharmaceutical and medical products business. Dr. Stoll was a member of the Board of Directors of the BOC Group, Plc, the parent company of Ohmeda, and also served on the Board of directors of St. Jude Medical. From 1986 to 1991, Dr. Stoll held several executive management positions at Bayer, AG including Executive Vice President and General Manager for the worldwide Diagnostic Business Group. Prior to that, Dr. Stoll worked for American Hospital Supply Corp., where he rose from Director of Clinical Pharmacology to President of the American Critical Care Division. He began his pharmaceutical career at the Upjohn Company, where he conducted human pharmacokinetic and drug metabolism clinical trials on various drugs in all phases of development. He currently serves on the Board of Directors of Chelsea Therapeutics and the School of Pharmacy Advisory Board of the University of Connecticut.

Commenting on today's announcement, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "As we move closer to the completion of our first Phase III clinical trial, and prepare for commercialization, the addition of the scientific and industry experience of Dr. Stoll will be an invaluable asset to our Company. His specific experiences in the areas of filtration, clinical testing and commercialization will provide important experience and input to projects currently underway at Delcath. We are fortunate that the promise of Delcath's PHP technology and the critical patient need that it addresses enables us to attract such experienced high caliber professionals to our Board."

**About Delcath Systems, Inc.**

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at [www.delcath.com](http://www.delcath.com).

*The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking*

---

statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

# # #

**Company Contact:**

Delcath Systems, Inc.  
Richard Taney  
(212) 489-2100  
[info@delcath.com](mailto:info@delcath.com)

**Public Relations Contact:**

Rubenstein Associates, Inc.  
Robin Wagge  
(212) 843-8006  
[rwagge@rubenstein.com](mailto:rwagge@rubenstein.com)